Top 10 Companies in the Medical Fibrin Adhesive Market (2026): Market Leaders Powering Global Surgery

MARKET INSIGHTS

Global Medical Fibrin Adhesive market size was valued at USD 1.41 billion in 2024 and is projected to grow from USD 1.48 billion in 2025 to USD 2.08 billion by 2032, exhibiting a CAGR of 5.0% during the forecast period.

Medical fibrin adhesives, also known as fibrin sealants or fibrin glue, are biocompatible agents that mimic the final stage of the natural coagulation cascade. Comprised of concentrated fibrinogen and thrombin, they rapidly form a stable fibrin clot that adheres to tissue surfaces, achieving hemostasis and promoting wound healing across a broad range of surgical procedures.

The market is expanding as surgical volumes rise worldwide, especially in cardiovascular, orthopedic, and plastic surgery, where effective hemostasis is essential. The biodegradability and low foreign‑body reaction of fibrin adhesives, combined with continuous product innovation such as ready‑to‑use kits and advanced application systems, drive adoption. Leading players like Baxter International, Johnson & Johnson (Ethicon), and CSL Behring dominate the landscape with extensive portfolios and aggressive global expansion strategies.

Medical Fibrin Adhesive Market – View in Detailed Research Report

---

Top 10 Companies in the Medical Fibrin Adhesive Market (2026)

1️⃣ Ethicon (Johnson & Johnson)

Headquarters: New Brunswick, New Jersey, USA
Key Offering: Tisseel® fibrin sealant kit, Tisseel® Plus, and Tisseel® Laparoscopic

Ethicon has long been the benchmark in hemostatic solutions, leveraging a deep R&D pipeline and a comprehensive regulatory footprint across North America, Europe, and Asia‑Pacific. The Tisseel® line is renowned for its predictable clotting profile and ease of use in complex reconstructive and minimally invasive procedures.

Sustainability & Growth Initiatives:

• Investment in recombinant fibrinogen to reduce donor dependency
• Partnerships with robotics vendors to integrate sealant delivery into automated platforms
• Commitment to achieving net‑zero carbon emissions in manufacturing by 2035

---

2️⃣ 3M Company

Headquarters: St. Paul, Minnesota, USA
Key Offering: 3M’s Solvent‑Based Fibrin Sealant and 3M Viscose™ adhesive system

3M’s portfolio spans solvent‑based and water‑based formulations, catering to cardiovascular and orthopedic indications. Their focus on high‑flow, rapid polymerisation systems supports procedures where speed is critical.

Sustainability & Growth Initiatives:

• Development of biodegradable solvent‑free formulations
• Expansion into veterinary and dental markets through tailored kits
• Investment in digital workflow integration for real‑time polymerisation monitoring

---

3️⃣ Baxter International

Headquarters: Deerfield, Illinois, USA
Key Offering: BAX 300, BAX 200, and BAX 100 fibrin sealant kits

Baxter’s product line is engineered for cardiovascular, cardiac, and major abdominal surgeries, with a focus on high‑strength clot formation and low immunogenicity.

Sustainability & Growth Initiatives:

• Recycling of packaging materials to reduce waste
• Collaboration with hospitals to optimise usage and reduce excess inventory
• R&D into autologous fibrin sealants for point‑of‑care applications

---

4️⃣ Takeda Pharmaceutical

Headquarters: Tokyo, Japan
Key Offering: Takeda Fibrin Sealant (TFS) and Takeda Fibrin Gel (TFG)

Takeda has broadened its hemostatic portfolio through strategic acquisitions of niche plasma‑derived technologies, enabling integrated solutions that combine sealants with adjunctive wound‑closure devices.

Sustainability & Growth Initiatives:

• Focus on cost‑effective manufacturing to support emerging markets
• Partnerships with local plasma banks to ensure supply chain resilience
• Development of single‑dose, ready‑to‑use kits for ambulatory settings

---

5️⃣ CryoLife

Headquarters: St. Paul, Minnesota, USA
Key Offering: CryoSeal® fibrin sealant and CryoSeal® Plus

CryoLife’s products are designed for rapid polymerisation and high‑strength clotting, targeting cardiac, vascular, and trauma applications.

Sustainability & Growth Initiatives:

• Optimization of cryopreservation processes to reduce energy consumption
• Expansion of product range to include hemostatic powders for hard‑to‑reach sites
• Investment in AI‑driven predictive analytics for surgical outcomes

---

6️⃣ Vivostat A/S

Headquarters: Hørsholm, Denmark
Key Offering: Vivostat® Autologous Fibrin Sealant System

Vivostat’s point‑of‑care system uses the patient’s own blood to create a custom fibrin sealant, eliminating donor‑related risks and improving safety profiles.

Sustainability & Growth Initiatives:

• Development of portable, single‑use cartridges for remote surgical sites
• Collaboration with medical device manufacturers to integrate the system into robotic suites
• Focus on reducing carbon footprint through streamlined manufacturing

---

7️⃣ Harvest Technologies (Terumo BCT)

Headquarters: Westlake, Ohio, USA
Key Offering: CryoSeal® platform and CryoSeal® Laparoscopic

Harvest’s CryoSeal® platform emphasizes ultra‑rapid polymerisation, ideal for minimally invasive procedures where time is at a premium.

Sustainability & Growth Initiatives:

• Integration of real‑time polymerisation sensors for clinician feedback
• Partnerships with hospitals to implement digital tracking of sealant usage
• Commitment to reducing single‑use plastic waste in packaging

---

8️⃣ Grifols

Headquarters: Barcelona, Spain
Key Offering: Grifols Fibrinogen and Thrombin products for commercial and laboratory use

Grifols leverages its plasma‑fractionation expertise to supply cost‑competitive bulk components, supporting manufacturers worldwide.

Sustainability & Growth Initiatives:

• Investment in renewable energy for plasma processing facilities
• Development of closed‑loop systems to recycle plasma‑derived waste
• Collaboration with global distributors to enhance supply chain transparency

---

9️⃣ CSL Behring

Headquarters: Marburg, Germany
Key Offering: CSL Behring Fibrin Sealant and CSL Behring Thrombin

CSL Behring’s product line is distinguished by high purity and consistent quality, enabling use in high‑risk surgical contexts.

Sustainability & Growth Initiatives:

• Adoption of ISO 14001 environmental management systems across facilities
• Development of low‑toxicity solvent‑free formulations
• Partnerships with academic centers for translational research

---

🔟 Integra LifeSciences

Headquarters: West Chester, Pennsylvania, USA
Key Offering: Integra Fibrin Sealant and Integra Surgical Adhesive System

Integra’s portfolio focuses on advanced tissue‑engineering applications, providing sealants that support regenerative healing.

Sustainability & Growth Initiatives:

• Investment in bio‑engineered fibrin matrices with tunable clotting properties
• Collaboration with robotics firms to integrate sealant delivery into automated platforms
• Commitment to circular economy principles in product packaging

---

Download FREE Sample Report

Get Full Report

---

Market Outlook (2026‑2034)

The market is positioned to reach USD 2.5 billion by 2034, with a steady CAGR of 4.8% from 2026. The upward trajectory is driven by the expanding volume of minimally invasive procedures, the increasing preference for biocompatible sealants in aesthetic and reconstructive surgeries, and the continual refinement of ready‑to‑use delivery systems.

Future Trends

• Personalized Bio‑Adhesives: Recombinant technologies will enable patient‑specific fibrin formulations, allowing surgeons to tailor clotting factor ratios to individual coagulation profiles.
• Digital Integration: Smart applicators embedded with sensors will provide real‑time polymerisation data, improving safety and enabling data‑driven surgical protocols.
• Regulatory Harmonisation: International alignment on plasma‑derived product standards will streamline market entry and reduce time‑to‑market.
• Emerging Markets: Rapidly urbanising economies in Asia‑Pacific and Latin America are expected to account for over 30% of the global growth, driven by increased surgical capacity and rising healthcare budgets.
• Supply‑Chain Resilience: Manufacturers will invest in diversified donor networks and advanced cryopreservation to mitigate supply disruptions.